Green Thumb Industries Inc banner
G

Green Thumb Industries Inc
CNSX:GTII

Watchlist Manager
Green Thumb Industries Inc
CNSX:GTII
Watchlist
Price: 11.26 CAD 1.72% Market Closed
Market Cap: CA$2.5B

P/FCFE

9.6
Current
70%
Cheaper
vs 3-y average of 32.6

Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.

P/FCFE
9.6
=
Market Cap
CA$2.2B
/
Free Cash Flow to Equity
$193.6m

Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.

P/FCFE
9.6
=
Market Cap
CA$2.2B
/
Free Cash Flow to Equity
$193.6m

Valuation Scenarios

Green Thumb Industries Inc is trading below its 3-year average

If P/FCFE returns to its 3-Year Average (32.6), the stock would be worth CA$38.08 (238% upside from current price).

Statistics
Positive Scenarios
4/4
Maximum Downside
No Downside Scenarios
Maximum Upside
+351%
Average Upside
201%
Scenario P/FCFE Value Implied Price Upside/Downside
Current Multiple 9.6 CA$11.26
0%
3-Year Average 32.6 CA$38.08
+238%
5-Year Average 43.5 CA$50.77
+351%
Industry Average 18.2 CA$21.25
+89%
Country Average 21.9 CA$25.53
+127%

Forward P/FCFE
Today’s price vs future free cash flow to equity

Not enough data available to calculate forward P/FCFE

Peer Comparison

All Multiples
P/FCFE
P/E
All Countries
Close
Market Cap P/FCFE P/E
US
Green Thumb Industries Inc
CNSX:GTII
2.6B CAD 9.6 16.3
US
Eli Lilly and Co
NYSE:LLY
908.9B USD 61.3 36
US
Johnson & Johnson
NYSE:JNJ
547.1B USD 21 26
CH
Roche Holding AG
SIX:ROG
248.4B CHF 27.5 20.1
UK
AstraZeneca PLC
LSE:AZN
209.6B GBP 36.2 27.4
CH
Novartis AG
SIX:NOVN
221.1B CHF 9.4 20.7
US
Merck & Co Inc
NYSE:MRK
277.6B USD 12.2 31.1
IE
Endo International PLC
LSE:0Y5F
244.4B USD -766.6 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.2T DKK 24.3 12.1
US
Pfizer Inc
NYSE:PFE
149.7B USD 24.3 19.3
US
Bristol-Myers Squibb Co
NYSE:BMY
118.9B USD 37.8 4 516.9
P/E Multiple
Earnings Growth PEG
US
G
Green Thumb Industries Inc
CNSX:GTII
Average P/E: 472.6
16.3
-21%
N/A
US
Eli Lilly and Co
NYSE:LLY
36
32%
1.1
US
Johnson & Johnson
NYSE:JNJ
26
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
27.4
25%
1.1
CH
Novartis AG
SIX:NOVN
20.7
14%
1.5
US
Merck & Co Inc
NYSE:MRK
31.1
14%
2.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
12.1
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.3
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
4 516.9
648%
7

Market Distribution

Lower than 80% of companies in the United States of America
Percentile
20th
Based on 7 576 companies
20th percentile
9.6
Low
0 — 13.1
Typical Range
13.1 — 36.5
High
36.5 —
Distribution Statistics
the United States of America
Min 0
30th Percentile 13.1
Median 21.9
70th Percentile 36.5
Max 3 188 432.5

Green Thumb Industries Inc
Glance View

Green Thumb Industries Inc., a notable player in the U.S. cannabis industry, operates like a well-tuned orchestra, harmonizing various elements of the cannabis business. The Chicago-based company is vertically integrated, meaning it controls each aspect of its product lifecycle—from cultivation to distribution. This structure enables Green Thumb to maintain consistency in its product quality while maximizing its operational efficiency. At the heart of its business model lies a diverse portfolio of well-regarded cannabis brands that cater to different consumer segments, from high-end connoisseurs to medicinal users seeking relief. These brands, including RYTHM, Dogwalkers, and Beboe, are strategically distributed across its extensive network of retail outlets, known as RISE dispensaries, as well as through wholesale channels. Like a savvy trader on a bustling market floor, Green Thumb’s profitability hinges on its ability to enhance scale while navigating the complex regulatory landscape. In each state where it operates, the company must tailor its approach to meet varying levels of regulation and market maturity. This agility provides Green Thumb with a competitive edge, allowing it to efficiently expand in both medical and adult-use markets while adhering to legal standards. The company generates revenue not only from its direct-to-consumer sales through dispensaries but also through wholesale transactions with other cannabis retailers. By maintaining robust relationships across these segments, Green Thumb underscores its position as a cornerstone of the cannabis industry's growth narrative.

GTII Intrinsic Value
12.45 CAD
Undervaluation 10%
Intrinsic Value
Price CA$11.26
G
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett